Duralis

Quick links to important sections

Duralis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Duralis

Property Description
Active ingredient Tadalafil
Form Oral film-coated tablet
Pharmacological class Selective Phosphodiesterase type 5 (PDE5) inhibitor
General Functional Basis Promotes localized vasodilation and enhanced blood flow
Origin Synthetic compound
Status Prescription-only (Rx)

Duralis is the trade name for a medicine that contains the active substance Tadalafil, which is specifically categorized as a selective Phosphodiesterase type 5 (PDE5) inhibitor. This medicinal entity is a synthetic compound, chemically characterized as a pyrazinopyrazinone derivative. As a substance with powerful systemic effects, Tadalafil necessitates that Duralis is dispensed only via prescription (Rx), as is standard for all PDE5 inhibitors.


The Definitive Identity of Duralis: Active Ingredient and Pharmacological Class

The fundamental identity of Duralis is defined by its sole active pharmaceutical ingredient, Tadalafil, a synthetic molecule designed for targeted biochemical intervention. Tadalafil's classification as a PDE5 inhibitor signifies that its primary functional role is to selectively block the action of the PDE5 enzyme throughout the body. Unlike older compounds with broader effects, Tadalafil exhibits a high degree of selectivity for the PDE5 enzyme, which is the clinical cornerstone of its efficacy. This selectivity focuses its action on the intended vascular targets.


Physical Form and General Therapeutic Principle

Duralis is manufactured as an oral film-coated tablet, a solid pharmaceutical preparation intended for convenient ingestion. The core therapeutic principle stems from Tadalafil's ability to inhibit PDE5, thereby preventing the rapid degradation of cyclic Guanosine Monophosphate (cGMP), a crucial secondary messenger. The resulting sustained increase in cGMP promotes smooth muscle relaxation and subsequently augments localized blood flow. This physiological outcome of enhanced circulation serves as the general functional basis for its use. Tadalafil possesses a prolonged terminal half-life, which imparts a notably longer duration of therapeutic effectiveness compared to other compounds within the PDE5 inhibitor class. This extended activity is a clinically recognized property that offers a wider therapeutic window.

Regulatory References

  1. Tadalafil Selectivity in StatPearls
  2. Tadalafil Pharmacokinetics (StatPearls)

What side effects are possible with Duralis?

Possible Side Effects and Safety Information

The safety profile for Duralis, containing Tadalafil, is defined by classifications based on regulatory documentation from agencies such as the FDA and EMA. Adverse reactions are grouped by their frequency and the physiological systems affected, reflecting the medicine's systemic vasodilatory properties.

Frequency-Classified Adverse Reactions

The most frequent reactions documented in regulatory sources fall into the Very Common and Common categories:

  • Very Common (1/10): Headache.
  • Common (1/100 to <1/10): Dyspepsia (indigestion), back pain, myalgia (muscle aches), flushing, and nasopharyngitis.

Less frequent reactions classified as Uncommon (1/1,000 to <1/100) include dizziness, blurred vision, hypotension, and palpitations. These effects primarily involve the nervous, musculoskeletal, and vascular system-organ classes.

Serious Adverse Reactions and Safety Constraints

Regulatory safety information outlines the potential for serious adverse reactions, which are typically rare but clinically significant. These include Priapism (a prolonged erection lasting four hours or more), sudden decrease or loss of vision (potentially indicative of Non-arteritic Anterior Ischemic Optic Neuropathy, or NAION), and sudden decrease or loss of hearing.

Official labeling defines strict safety constraints, noting that use is contraindicated in patients who are simultaneously taking any form of organic nitrate or Guanylate Cyclase (GC) Stimulators due to the risk of severe hypotension. Furthermore, use is not recommended in patients with severe hepatic (liver) impairment or severe renal (kidney) impairment.

Overdose and Emergency Response

The official regulatory profile for Tadalafil (Duralis) overdose centers on the exaggeration of its expected pharmacological effects and the occurrence of time-critical adverse events. Overexposure may result in severe manifestations such as headache, myalgia (muscle pain), flushing, and significant systemic hypotension.

The regulatory labeling explicitly identifies several conditions that constitute medical emergencies requiring immediate action. Priapism, defined as an erection lasting >4 hours, requires patients to seek emergency treatment without delay to prevent the risk of irreversible tissue damage and permanent loss of potency. Additionally, a sudden loss of vision or sudden decrease or loss of hearing necessitates that the medication be discontinued and prompt medical attention be sought. Serious cardiovascular events, including myocardial infarction and ventricular arrhythmia, have also been reported in association with use.

In the event of overdosage, patients must seek immediate medical attention. Management is formally limited to symptomatic and supportive measures, as no specific antidote is described in the prescribing information. Furthermore, hemodialysis is not expected to accelerate clearance due to the drug's extensive plasma protein binding. Population-specific considerations note that patients with severe renal impairment have a documented increased Tadalafil exposure, which elevates the potential for toxicity during overexposure.

Therapeutic Uses of Duralis

What Duralis Treats: Main Uses and Benefits


The therapeutic uses of Duralis are precisely defined, covering several key areas of physiological functioning. This medication is applied in situations involving certain distressing symptoms related to systemic imbalance and localized functional stress.

Enhancing Erectile Function

Duralis is commonly used to address symptoms of Erectile Dysfunction (ED), supporting adult men who struggle with achieving or maintaining an erection firm enough for satisfactory sexual activity. This use contributes to the therapeutic benefit of improving sexual function and may assist with maintaining functional stability during periods where symptoms interfere with intimate relations.

Relieving Lower Urinary Tract Symptoms

This medication is also relevant for easing the disruptive Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH), such as urinary frequency and a weak stream. By easing these obstructive and irritative manifestations, Duralis provides supportive relief when symptoms interfere with routine activities, contributing to improved day-to-day comfort.

Supporting Physical Capacity in Pulmonary Hypertension

Duralis is applied to support patients with Pulmonary Arterial Hypertension (PAH), which is marked by symptoms like shortness of breath and fatigue that limit physical activity. It provides a crucial therapeutic benefit by addressing symptoms related to systemic imbalance and assists with maintaining functional stability during chronic management.


Quick Fact: Relief for Physical Functioning

Duralis may assist with managing functional strain across multiple body systems, including supporting sustained erectile function, easing bothersome urinary symptoms, and helping to maintain physical activity in PAH patients.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility and Contraindications for Duralis (Tadalafil)

The official regulatory documentation strictly defines the populations eligible to use Duralis, primarily based on contraindications and organ function status. Use is permitted for adult men with Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia (BPH), and for adults (men and women) with Pulmonary Arterial Hypertension (PAH).


Absolute Prohibitions

The medicine is contraindicated and must not be used by patients taking any form of organic nitrates or Guanylate Cyclase (GC) Stimulators (e.g., riociguat), due to the risk of severe hypotension. Contraindication also applies to patients with a history of Non-arteritic anterior ischemic optic neuropathy (NAION) or certain recent serious cardiovascular events, such as a myocardial infarction within the last 90 days or a stroke within the last 6 months.


Restricted and Non-Established Use

Use is not recommended for patients with severe hepatic impairment or severe renal impairment (for once-daily dosing). While use for PAH is approved in pediatric patients (ages 2 and older), the medicine is not established for use in the pediatric population for the ED or BPH indications. Caution is advised for women who are breastfeeding and for patients predisposed to priapism.

What should I know about interactions with other medicines?

Duralis (tadalafil) can interact with several medicinal products, potentially leading to serious health risks due to changes in blood pressure or drug levels.

Contraindicated Combinations

Co-administration with organic nitrates in any form (such as nitroglycerin, isosorbide dinitrate, or isosorbide mononitrate) is strictly contraindicated. This is due to a risk of a sudden, severe, and dangerous drop in blood pressure (hypotension). This restriction also applies to guanylate cyclase (GC) stimulators, such as riociguat, which, when combined, can also cause life-threatening hypotension.

Interactions Affecting Drug Levels

Duralis is metabolized primarily by the CYP3A4 enzyme system in the liver. Products that strongly inhibit this enzyme, such as certain antifungal agents (e.g., ketoconazole) and protease inhibitors (e.g., ritonavir), can significantly increase the level of Duralis in the bloodstream, raising the risk of side effects. Conversely, strong CYP3A4 inducers, such as rifampin, can decrease Duralis levels, potentially reducing its effectiveness.

Other Combinations Requiring Caution

  • Alpha-blockers and other antihypertensive medicines (for high blood pressure) may have additive blood pressure-lowering effects when taken with Duralis, necessitating careful monitoring or dose adjustment.
  • Other PDE5 inhibitors (e.g., sildenafil) should not be used concurrently as there is no proven additional benefit, and the risk of common side effects is increased.
  • Consumption of substantial amounts of alcohol can also contribute to an increased risk of hypotension, dizziness, and fainting.

Mechanism of Action

Duralis functions as a selective inhibitor of phosphodiesterase type 5 (PDE5), a key enzyme expressed primarily in smooth muscle cells across various tissues. This interaction type involves the drug binding to the active site of PDE5, thereby preventing the enzyme from catalyzing the breakdown of cyclic guanosine monophosphate (cGMP).

This specific inhibition results in a concentration-dependent increase in cGMP, which constitutes the intracellular molecular consequence. Elevated cGMP levels in turn augment the signaling cascade initiated by nitric oxide (NO) release, as the cGMP molecules persist longer to activate downstream protein kinases.

At the system level, this augmented pathway modulation initiates smooth muscle relaxation. This physiological consequence is mediated through the phosphorylation of various cellular substrates, leading to changes in intracellular calcium dynamics and the resulting modulation of vascular tone in affected tissues.

Dosage and Administration Information

Duralis is designated for oral use only, administered as a film-coated tablet in official strengths ranging from 2.5 mg to 40 mg. The correct administration pattern is strictly determined by the condition being addressed. The tablet should be swallowed whole and must not be split or divided. It can be taken without regard to food.


Official Dosing Regimens and Frequency

The official dosage schedule adheres to distinct patterns based on the condition being addressed, defining whether the use is continuous or episodic:

Condition / Use Pattern Typical Dosing Schedule Administration Details
Erectile Dysfunction (ED) – As Needed Starting dose is 10 mg, adjusted up to 20 mg. Must be taken at least 30 minutes prior to activity. Maximum once per day.
ED or BPH – Once Daily Use 2.5 mg or 5 mg once daily. Taken at the same time every day.
Pulmonary Arterial Hypertension (PAH) Fixed dose of 40 mg once daily. Must not be divided throughout the day.

Administration Context and Adjustments

For once-daily regimens, consistency in timing is required. If a dose is missed, the next dose should be taken as scheduled without taking two doses to compensate. This medication is subject to high-level dose or frequency modifications for patients with reduced organ function. For individuals with severe renal impairment (CrCl less than 30 mL/min), continuous daily use for ED/BPH and the PAH dose are officially not recommended or must be avoided. Similarly, use is not recommended in cases of severe hepatic impairment. These rules define the standardized approach to using the medicine.

Recent Clinical Evidence

Duralis: Recent Clinical Evidence

Clinical research exploring Duralis (Tadalafil) was conducted in controlled settings across three distinct clinical situations: Erectile Dysfunction (ED), Lower Urinary Tract Symptoms (LUTS) associated with BPH, and Pulmonary Arterial Hypertension (PAH). The evidence primarily comes from rigorous, placebo-controlled Randomized Controlled Trials (RCTs) and subsequent meta-analyses. Research provides context but not individual predictions.


Evidence for use in Erectile Dysfunction (ED)

Studies enrolling adult men with ED examined outcomes related to daily functioning using the standardized IIEF-EF domain score. Research documenting measured differences in the IIEF-EF scores when comparing the treated groups against the placebo groups. This evidence contributes to understanding short-term symptom patterns and intermediate periods (over a daily mathbf12 -week course). Data on outcomes over extended periods beyond this timeframe are not fully established.

Evidence for use in Lower Urinary Tract Symptoms (LUTS)

The study of LUTS associated with BPH was explored in multiple short-term, mathbf12 -week placebo-controlled RCTs. Researchers examined the severity of LUTS using the International Prostate Symptom Score (IPSS) and associated quality of life. Studies reported the measurements of the IPSS total score recorded when comparing the daily regimen to the placebo. Reported data on objective measures like the maximum urinary flow rate (Q max) showed that these changes were modest or varied across the combined study protocols.

Evidence for use in Pulmonary Arterial Hypertension (PAH)

Research for PAH involved pivotal, large-scale, mathbf16 -week placebo-controlled RCTs. Researchers examined outcomes related to daily functioning using the 6-Minute Walk Distance (6MWD) and monitored time to clinical worsening. Follow-up data described that the 6MWD measurements in the continued-treatment cohort were reported at levels consistent with the outcomes measured in the initial trial for up to mathbf52 weeks.

Areas of Research Uncertainty and Study Gaps

Comparative evidence is lacking for direct head-to-head comparisons against all other medications in the same pharmacological class and against competing therapeutic options. Furthermore, for conditions like PAH, dedicated research on the long-term impact on survival rates remains insufficient. Research examining physical outcomes for BPH, such as the objective urinary flow rate (Q max), reported findings that were mixed or modest across some studies.

Key Studies & References

  1. Tadalafil therapy for pulmonary arterial hypertension (PHIRST): a randomised, double-blind, placebo-controlled, parallel-group multicentre trial

Frequently Asked Questions (FAQ)

Common questions about Duralis (FAQ)

Q: How quickly should I expect to feel a change after starting Duralis?

A: According to regulatory documents, when the medicine is used as needed for certain conditions, the medicine is noted to be taken at least 30 minutes before activity. For chronic, once-daily use for conditions like BPH or PAH, the official information does not typically describe the exact time-to-effect in terms of minutes or hours, as the benefits build up over time.

Q: Does Duralis cause drowsiness or affect my ability to focus?

A: Official documentation lists dizziness as an uncommon side effect, meaning it occurs in fewer than 1 out of 100 people. If dizziness or changes in vision occur, regulatory labeling includes a caution regarding driving or operating machinery.

Q: Are there any foods or drinks I should avoid while taking Duralis (e.g., grapefruit juice)?

A: Official labeling states the medicine can be taken with or without food. However, based on how the body processes the medicine through the CYP3A4 enzyme system, regulatory information advises caution with substances that are strong inhibitors of this enzyme. The interaction with grapefruit juice is typically noted in product information.

Q: Can Duralis be used by people with high blood pressure or heart conditions?

A: Official documents list specific recent serious heart and vascular events, such as a heart attack within 90 days or a stroke within 6 months, as contraindications. For chronic conditions like high blood pressure, caution is noted because the medicine may have an additive blood pressure-lowering effect if taken with other antihypertensive drugs.

Q: Is Duralis safe to take if I am pregnant or breastfeeding, according to regulatory documents?

A: Regulatory documents state that caution is advised for women who are breastfeeding. Information on the use of the medicine during pregnancy is often limited, and for most uses, it is not fully established.

Q: Are there any large, long-term studies that have been published about Duralis?

A: The research evidence for the medicine comes from controlled clinical trials. These studies generally establish outcomes for periods ranging from 12 to 16 weeks. For the PAH indication, extended follow-up data for up to 52 weeks has also been reported in official documents.

Q: How long does Duralis stay in my system after I stop taking it?

A: Studies of the medicine's pharmacology indicate that its active ingredient has a prolonged half-life of 17.5 hours. The half-life is the time it takes for half of the drug to leave the bloodstream. It generally takes about five times the half-life for a medication to be considered fully eliminated from the body.

Q: Is Duralis the kind of medicine that you have to take every day?

A: No. Official dosing regimens allow for two main patterns of use, depending on the condition being addressed. The medicine can be taken either once daily on a continuous schedule, or it can be taken as needed before a specific activity.

Q: What is the half-life of Duralis, according to the pharmacology data?

A: The pharmacology data, found in official regulatory documents, indicates that the terminal half-life of the active ingredient, Tadalafil, is 17.5 hours. The half-life is a measure of how quickly the substance is cleared from the bloodstream.

Q: Does Duralis interact with any other prescription drugs for chronic conditions?

A: Yes, the regulatory documentation describes specific interactions with several classes of prescription medicines commonly used for chronic conditions. These include alpha-blockers, other agents for high blood pressure, and medications that affect the CYP3A4 enzyme system in the liver.

Q: Can Duralis interfere with my ability to drive or operate machinery?

A: Yes, the official labeling generally advises caution regarding activities like driving or operating machinery. This warning is included because some patients experience side effects such as dizziness or changes in vision.

Q: Is the effectiveness of Duralis impacted by my diet?

A: The regulatory information states that the medicine can be administered without regard to food. This indicates that food intake at the time of administration does not impact its effectiveness.

Q: Why is it important to tell my doctor about all my existing medical conditions before taking Duralis?

A: It is important because official documents strictly define who can and cannot use the medicine based on existing health issues. The medicine is contraindicated (prohibited) for certain heart events and is not recommended for patients with severe liver or kidney problems due to safety constraints.

Q: Can Duralis make certain pre-existing conditions worse?

A: Regulatory documentation specifies conditions that require caution or where the medicine is not recommended. For instance, its use is not recommended for individuals with severe hepatic (liver) or renal (kidney) impairment. Caution is also advised for patients predisposed to a prolonged erection (priapism).

Q: What is the general mechanism of action of Duralis, explained simply?

A: The medicine is classified as a selective Phosphodiesterase type 5 (PDE5) inhibitor. This means it works by blocking the PDE5 enzyme, which causes the smooth muscles in specific tissues to relax. This relaxation ultimately promotes enhanced, localized blood flow, which is the general functional basis for its uses.

Q: What is the main difference between Duralis and other similar medicines for this condition?

A: Regulatory data notes that a key differentiating property is that the active ingredient possesses a prolonged terminal half-life compared to other compounds in the same pharmacological class. This extended activity is a clinically recognized property.

Q: Why is Duralis prescribed for my condition when I heard people use it for something else?

A: The official regulatory documents strictly define the approved conditions for which the medicine is indicated. The primary approved uses listed in these documents are Erectile Dysfunction (ED), Benign Prostatic Hyperplasia (BPH), and Pulmonary Arterial Hypertension (PAH).

Q: Can I safely take over-the-counter pain relievers like Ibuprofen or Tylenol while on Duralis?

A: Regulatory labeling advises caution with medications that have blood pressure-lowering effects, which may include certain over-the-counter pain relievers. Product information notes caution with certain blood pressure-lowering agents.

Q: What is the risk of dependence or addiction associated with Duralis?

A: According to regulatory documents, the medicine has no known potential for abuse or dependence. It is not classified as a controlled substance by regulatory bodies.

Q: How does the strength or dose of Duralis relate to the severity of the condition it treats?

A: Regulatory documents specify distinct doses depending on the condition being treated, such as PAH versus ED. Furthermore, the official prescribing information outlines how the dose may be adjusted based on the patient's individual response and tolerability.

Q: What does 'contraindication' mean in the context of Duralis?

A: A contraindication is a condition or factor that serves as a reason to withhold a certain medical treatment because the potential harm it would cause the patient outweighs any potential benefit. In the context of this medicine, contraindications include taking certain other medications or having specific recent cardiovascular events.

Q: Is it true that Duralis is not recommended for people over 65?

A: Official regulatory labeling does not state a general age-based restriction that prohibits use in people over 65. However, it is noted that older patients may have a greater risk of reduced organ function, which is a factor that physicians consider when determining eligibility.

Q: Can Duralis interact with herbal supplements like St. John's Wort?

A: Regulatory documents caution against using strong inducers of the CYP3A4 enzyme system because they can significantly lower the level of the medicine in the bloodstream, reducing its potential effectiveness. Some herbal supplements, such as St. John's Wort, are known inducers of this enzyme system.

Q: What is the difference between a side effect and an adverse reaction to Duralis?

A: Official medical terminology generally defines a side effect as an expected or secondary non-harmful effect of a medicine. An adverse reaction, however, is an unintended and undesirable effect that may be serious and sometimes requires a change in treatment.

Q: Is Duralis FDA-approved or approved by another regulatory body?

A: Yes, the medicine is approved and registered by major health authorities. The detailed labeling is provided by agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Q: What are the signs of a possible overdose for Duralis?

A: According to regulatory documents, the symptoms of a possible overdose typically mirror the known common side effects, such as headache, flushing, or back pain. These effects would be expected to occur with increased intensity.

Q: Does Duralis have a boxed warning or 'Black Box Warning' listed by the FDA?

A: The official labeling of a medicine will clearly state if the US Food and Drug Administration (FDA) has required a specific Boxed Warning to be included. This is a prominent warning required for certain serious risks that may be associated with the drug.

Q: What is the meaning of the warnings and precautions section for Duralis?

A: The Warnings and Precautions section in regulatory documentation outlines specific conditions or situations where the medicine should be used with extra care. This section is included because the risk of a serious adverse event may increase under these circumstances.

Q: Do studies suggest Duralis is less effective for certain age groups?

A: Studies indicate that the effectiveness of the medicine in older patients (aged 65 years and over) is generally consistent with the effectiveness seen in younger patients. Clinical trial reports often include these types of subgroup analyses.

How should Duralis be stored and disposed of?

Duralis should be stored precisely according to the directions provided on the product labeling and by your pharmacist. Typically, most medicines require storage in a cool, dry place, protected from excessive moisture and heat, such as those found in a bathroom medicine cabinet. It is essential to keep Duralis in its original container and safely out of the sight and reach of children and pets to prevent accidental ingestion.

Never use Duralis past its expiration date. When disposing of expired or unused medication, do not flush it down a toilet or pour it down a drain unless specifically instructed to do so by the manufacturer or the FDA, as this can contaminate the water supply. The preferred disposal method for most medicines is to utilize a community drug take-back program or a medication disposal kiosk, often available at local pharmacies or law enforcement sites. If a take-back option is unavailable, you can dispose of the medicine in your household trash by mixing it with an unappealing substance, like dirt or used coffee grounds, placing the mixture in a sealed bag, and then throwing it away. Be sure to obscure or remove all personal information from the container before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Duralis found in:

A-Z Index: